Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ScRNAseq of longitidunally acquired samples from a CLL patient

ABSTRACT: We collected three timepoint blood samples from a CLL patient underwent BTK inhibitor treatment. We performed single cell RNA sequencing on these samples to track expression heterogeneity of malignant B-cell populations over time.

ORGANISM(S): Homo sapiens

PROVIDER: GSE186150 | GEO | 2021/10/22

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

scRNAseq of longitidunally acquired samples from a CLL patient

Project description:scRNAseq of longitidunally acquired samples from a CLL patient

| PRJNA772744 | ENA

RNA sequencting of CLL cells treated by BTK degrader

Project description:BTK plays a critical role in B cell malignancies survival. BTK inhibitor was successfully used as first line treatment for CLL in clinical. The emerging unmet needs is new segments are needed for ibrutinib R/R patients. The purpose of this study is to investigate genomic changes and signaling pathway differences after CLL cells were treated with BTK inhibitor (ibrutinib) or degrader (NRX0492).

2022-03-19 | GSE198992 | GEO

Single cell landscape of MBL/CLL transition [MBL_CLL_GEO_DataSet3]

Project description:The transition of monoclonal B cell lymphocytosis (MBL) to chronic lymphocytic leukemia (CLL) remains ill-defined at the epigenetic and transcriptional level. Here, we performed single cell RNA and ATAC sequencing of low-count (LC) and high-count (HC) MBL and CLL blood samples to track the continuum from physiologic B cells to CLL.

2026-03-31 | GSE295491 | GEO

Single cell landscape of MBL/CLL transition [MBL_CLL_GEO_DataSet2]

2026-03-31 | GSE295490 | GEO

Single cell landscape of MBL/CLL transition [MBL_CLL_GEO_DataSet1]

2026-03-31 | GSE295489 | GEO

Defining the acute BTK-loss transcriptional program in CLL using a BTK degrader

Project description:Defining the acute BTK-loss transcriptional program in CLL using a BTK degrader by RNA-seq

2026-03-11 | GSE319429 | GEO

Mutational analysis of CLL patient samples

Project description:Mutational analysis of CLL patient samples

| PRJEB97782 | ENA

Ribosome profiling of CLL patient samples

Project description:Ribosome profiling of CLL patient samples

| PRJEB23398 | ENA

CITE-Seq profiling of CLL under ibrutinib treatment reveals transcriptional evolution of leukemic and immune cells.

Project description:Ibrutinib, an irreversible Bruton Tyrosine Kinase (BTK) inhibitor, has revolutionized Chronic Lymphocytic Leukemia (CLL) treatment, but resistances to ibrutinib have emerged in relation or not to BTK mutations. Evolution patterns of CLL before and after ibrutinib therapy are often focused only on leukemic cells but must be investigated in the context of the CLL microenvironment. Single cell RNA-seq and related technologies allow a deeper characterization of cancer and normal cells. We therefore investigated whether ibrutinib treatment drives molecular changes in CLL. Here, we report the monitoring of a CLL patient under ibrutinib treatment using Cellular Indexing of Transcriptomes and Epitopes by sequencing (CITE-Seq) technology. We report that the short clinical relapse of this patient, driven by BTK mutation, is associated with intra-clonal heterogeneity and transcriptional and phenotypical modifications in both B leukemic and immune cells. These results open new therapeutic strategies for ibrutinib-refractory CLL patients.

2020-12-15 | GSE152469 | GEO

The Proteome Landscape of Chronic Lymphocytic Leukemia (CLL)

Project description:Many functional consequences of mutations on tumor phenotypes in chronic lymphocytic leukemia (CLL) are only partially known. This is in part due to a scarcity of information on the proteome of CLL. We profiled the proteome of 117 CLL samples with data-independent acquisition mass spectrometry (DIA-MS) and integrated the results with genomic, transcriptomic, functional data and clinical outcome. We found trisomy 12 and IGHV to be major determinants of proteome variation in CLL (1055 and 542 differential proteins FDR of 5%). Trisomy 12 was associated with limited protein abundance buffering. Protein complex analyses detected functional units involved in BCR/PI3K/AKT signaling in CLL with trisomy 12. We associated protein expression with response to anticancer drugs, and STAT2 protein expression emerged as a biomarker for the prediction of response to kinase inhibitors including BTK and MEK inhibitors. STAT2 protein levels were determined by gene dosage (trisomy 12), stabilization in a protein complex and linked to interferon signaling in CLL. This study highlights the emerging importance of protein abundance profiling in CLL biology.

2021-09-24 | PXD022198 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data